SYNDAX PHARMACEUTICALS INC (SNDX)
Health Care · Clinical-stage biopharmaceutical oncology and fibrotic disease therapies · NASDAQ
Syndax Pharmaceuticals is a clinical-stage and commercial-stage biotechnology company developing a pipeline of targeted cancer therapies, including approved treatments for leukemia and chronic graft-versus-host disease.
What SYNDAX PHARMACEUTICALS INC does
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company that develops and commercializes therapies for cancer and fibrotic diseases. The company has two FDA-approved marketed products: REVUFORJ (revumenib), an oral selective menin inhibitor, and NIKTIMVO (axatilimab-csfr), which it co-develops and commercializes through a collaboration with Incyte Corporation. Syndax operates through licenses with major pharmaceutical partners including UCB Biopharma and AbbVie (through Vitae Pharmaceuticals), and generates revenue from product sales and collaboration arrangements.
Themes: oncology therapeutics, hematology treatments, targeted cancer therapy, menin inhibition, chronic graft-versus-host disease
Fundamentals
- Price$19.65 as of 2026-08-21 close
- Market cap$1.8B as of 2026-08-21
- 1-year return+24.1% 2025-08-21 close $15.84 → 2026-08-21 close $19.65
- P/En/a negative earnings
- Net margin-87.5% as of 2026-08-24
- Gross margin+95.8% as of 2026-08-24
- ROE-372.9% as of 2026-08-24
- Debt / equity38.95 as of 2026-08-24
- Revenue growth (YoY)+222.7% as of 2026-08-24
- Beta0.42 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How SNDX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How SYNDAX PHARMACEUTICALS INC looks technically
SYNDAX PHARMACEUTICALS INC (SNDX) is trading 5.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 1 trading day ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It made a new 20-day low about 16 trading days ago. It is 23.2% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 5.1% below its 200-day average, the long-term trend line — a long-term downtrend | -5.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $20.73 | $20.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $20.71 | $20.71 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 17.2. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 1 trading day ago — a "golden cross", a bullish long-term signal | 1 session |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control | 30.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 45.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($17.20 to $20.88) — its "stochastic" reading is 67 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 66.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $25.59 | $25.59 |
|---|---|---|
| From the 52-week high | it is 23.2% below its 52-week high (its highest price of the past year) | -23.2% |
| Above the 52-week low | it is 51.3% above its 52-week low (its lowest price of the past year) | +51.3% |
| Below the 52-week high | it is 23.2% below its highest point of the past year | 23.2% |
| Since a 20-day breakout | it made a new 20-day low about 16 trading days ago | 16 sessions |
| Since a 55-day breakout | it made a new 55-day high about 32 trading days ago | 32 sessions |
| All-time high | its highest closing price on record is $29.86 (set on 2023-02-02) | $29.86 |
| Given back of the 52-week move | over the past year its closes ranged ($13.11 to $25.15), and it has given back around half of its rise from last year’s low — 46% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.32 to $17.71. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 45.7% |
| From the all-time high | it is 34.2% below its all-time high | -34.2% |
| Nearest price level | it is sitting right on a support level at $19.59 — a price it turned at twice since 2026-01-05, most recently on 2026-01-13. Since 2024-08-21 it has 10 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.3% |
| All-time low | its lowest closing price on record is $3.39 (set on 2018-12-26) | $3.39 |
| Above the all-time low | it is 479.6% above its all-time low | +479.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 89% of it) | 11th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.01 between its high and its low — about 5.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.01 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $18.80 and $20.76 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $18.80 – $19.78 – $20.76 |
| Typical daily range (% of price) | its price moves about 5.1% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.1% |
| Stretch from the 200-day average | it is trading 1.1 daily ranges below its 200-day average price (5.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.20× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.0% since the prior reading | -0.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 2.4% above the previous close 49 sessions ago and has not traded back through the level it left behind at 16.96 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.4% |
| Gap filled | a 3.6% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.39% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 15.5 percentage points (the stock lost 13.2% while the market gained 2.3%) | -15.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 3.7 percentage points (the stock lost 0.6% while the market gained 3.1%) | -3.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 11.3 percentage points (the stock lost 0.2% while the market gained 11.1%) | -11.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 3.6 percentage points (the stock gained 24.1% while the market gained 20.5%) | +3.6% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.2% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 5.8% of the share price. | -6.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $21.29 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -7.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $19.84 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | -0.9% |
Price levels it has turned at before
SNDX last closed at $19.65 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $19.59 | Support | 0.3% below the last close | turned there twice · 2026-01-05 to 2026-01-13 |
| $19.01 | Support | 3.3% below the last close | turned there four times · 2026-02-27 to 2026-08-14 |
| $18.54 | Support | 5.7% below the last close | turned there twice · 2024-10-23 to 2024-11-04 |
| $22.30 | Resistance | 13.5% above the last close | turned there five times · 2024-11-11 to 2026-03-30 |
| $22.71 | Resistance | 15.6% above the last close | turned there twice · 2025-12-23 to 2026-05-11 |
| $25.38 | Resistance | 29.1% above the last close | turned there four times · 2026-03-10 to 2026-07-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $17.20.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $25.78 and $31.08 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $17.20.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$37.55 range $26.00 – $57.00; median $37.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SNDX
- Consensus EPS estimate-$0.4703 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy dependence on collaboration revenue and milestone payments from Incyte and other licensors; ability to maintain licenses with UCB and Vitae/AbbVie is critical to continued operations","Clinical efficacy and safety of product candidates may not be replicated in future trials; regulatory approval timing and likelihood remain uncertain","Market adoption of REVUFORJ and NIKTIMVO by physicians and patients is not assured; failure to achieve commercial traction would severely impact revenues"]
What changed in the latest 10-Q
AI-assisted comparison of SNDX's 10-Q filed 2026-04-30 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-04-30) adds specific Q1 2026 revenue data: Revuforj achieved $48.9 million in net revenue with 144% increase over Q1 2025 and 11% increase over Q4 2025
- Newer filing adds analysis that nearly half of KMT2A patients proceed to HSCT after Revuforj treatment, compared to prior estimates of 33%
- Newer filing adds expectation that growing HSCT transplant rate will extend average treatment duration as patients return to therapy post-transplant
- Newer filing adds detailed section on 'Recent Business Highlights and Anticipated Milestones' with specific data expected throughout 2026
- Newer filing adds multiple specific clinical trial data expectations for Q2 2026 and second half of 2026
- Newer filing adds REVEAL-ND trial description: Phase 3 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m AML patients
- Newer filing adds RAVEN trial expected to initiate in second half of 2026: Phase 2 collaborative trial in newly diagnosed KMT2Ar patients
- Newer filing specifies accumulated deficit as of March 31, 2026 of $1.5 billion and cash/equivalents/short-term investments of $352.1 million
- Newer filing reports net loss of $42.7 million for three months ended March 31, 2026 versus $84.8 million for three months ended March 31, 2025
- Removed:
- Older filing (2025-11-03) mentions exploration of revumenib activity in metastatic colorectal cancer as a solid tumor indication; newer filing does not mention this
- Older filing references 'Business Update' section header; newer filing uses 'Recent Business Highlights and Anticipated Milestones'
- Older filing reports nine months ended September 30, 2025 net loss of $217.4 million and accumulated deficit of $1.4 billion; these period-specific metrics are removed in newer filing
- Older filing reports cash, equivalents and short- and long-term investments of $456.1 million as of September 30, 2025; newer filing provides different date and lower amount
- Older filing describes EVOLVE-2 trial as evaluating patients 'who are unfit for intensive chemotherapy' without mentioning KMT2Ar in primary population; newer filing adds KMT2Ar patients to EVOLVE-2 description
- Older filing references 'Start-up activities underway for two trials, known as the REVEAL trials' with expected initiation by end of 2025; newer filing updates this with REVEAL-ND as pivotal Phase 3 trial already in progress
- Reworded:
- Older filing: 'two commercially approved products'; newer filing: 'two commercially approved medicines'
- Older filing: 'no satisfactory alternative treatment option' (singular); newer filing: 'no satisfactory alternative treatment options' (plural)
- Older filing: 'KMT2A-rearranged acute leukemia'; newer filing introduces abbreviation 'KMT2Ar' and uses this abbreviation consistently throughout
- Older filing: 'exploring the use of revumenib as a treatment in solid tumors'; newer filing: 'exploring the potential for menin inhibition in the treatment of myelofibrosis'
- Older filing: 'We have begun generating product revenue'; newer filing: 'While we generate product revenue' (implies ongoing status)
- Older filing describes EVOLVE-2 as evaluating 'newly diagnosed NPM1m AML patients'; newer filing specifies 'newly diagnosed NPM1m (primary efficacy analysis population) and KMT2Ar AML patients'
- Older filing states 'The trial is being conducted by investigators from MD Anderson Cancer Center' for SAVE; newer filing identical for SAVE trial description
- Older filing: 'Intensive chemotherapy: Two ongoing Phase 1 trials evaluating the combination of revumenib with intensive chemotherapy (7+3) followed by revumenib maintenance treatment'; newer filing: 'Intensive chemotherapy: Two ongoing Phase 1 trials evaluating the combination of revumenib with intensive chemotherapy (7+3) in newly diagnosed'
- Notes:
- The newer filing appears truncated at the end of the Revuforj section; the RAVEN trial description ends mid-sentence ('...in newly diagnosed KMT2Ar patients who wo')
- Older filing referenced Form 10-K filed March 3, 2025; newer filing references Form 10-K filed February 26, 2026, indicating updated annual report timing
- Older filing included data on Niktimvo revenue and ASH meeting presentations; newer filing excerpt does not include Niktimvo section (may be present but not provided in comparison texts)
Risk Factors
- Added:
- Newer filing (2026-04-30) includes 'Collaboration revenue, net' line item of $15,941 thousand for three months ended March 31, 2026
- Newer filing (2026-04-30) reports 'Collaboration loss' line of $0 thousand in operating expenses (compared to $247 thousand in older filing's 2025 comparative period)
- Newer filing (2026-04-30) shows accounts receivable of $38,116 thousand at March 31, 2026 (versus $25,403 thousand at September 30, 2025 in older filing)
- Newer filing (2026-04-30) includes 'Inventory, net' of $34,948 thousand at March 31, 2026 (older filing shows 'Inventory' of $25,000 thousand at September 30, 2025)
- Removed:
- Older filing (2025-11-03) includes 'Long-term investments' line item ($20,146 thousand at September 30, 2025) that does not appear in newer filing's balance sheet
- Older filing (2025-11-03) includes 'Collaboration payable, net' line item ($0 thousand at September 30, 2025) that does not appear in newer filing
- Older filing (2025-11-03) includes 'Current portion of royalty interest financing liability' ($22,925 thousand at September 30, 2025) as separate line item; newer filing consolidates this into liabilities differently
- Older filing (2025-11-03) shows 'Milestone and license revenue' line item ($0 thousand in three months ended September 30, 2025) not present in newer filing
- Reworded:
- Older filing (2025-11-03) labels 'Accounts receivable, net' whereas newer filing (2026-04-30) labels 'Accounts receivable' without 'net' designation
- Older filing (2025-11-03) labels 'Inventory' whereas newer filing (2026-04-30) labels 'Inventory, net'
- Notes:
- The two filings cover different fiscal periods (three months ended March 31, 2026 versus nine months ended September 30, 2025), which may account for some structural and numerical differences beyond substantive accounting changes
- Balance sheet comparison dates differ materially (March 31, 2026 versus September 30, 2025 and December 31, 2024), limiting direct comparability
- The newer filing text appears truncated at the end of the Nature of Business section, potentially omitting additional disclosures
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 5 sells ($2M) — 3 selling insiders
- Last 180 days0 buys · 5 sells ($2M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-08. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SNDX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SNDX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 14,124,237
- Reported value $329,942,171
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SNDX had 22,665,216 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SNDX had 25.4% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 18.58 days to cover at the same settlement.
- Reported short interest (shares) 22,665,216
- Short interest (% of shares outstanding) 25.4%
- Prior settlement (shares) 20,816,110
- Reported change 8.88%
- Days to cover (reported) 18.58
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SNDX vs…
SYNDAX PHARMACEUTICALS INC is found in…
SNDX ranks in…
Frequently asked questions
What does SYNDAX PHARMACEUTICALS INC (SNDX) do?
Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company that develops and commercializes therapies for cancer and fibrotic diseases. The company has two FDA-approved marketed products: REVUFORJ (revumenib), an oral selective menin inhibitor, and NIKTIMVO (axatilimab-csfr), which it co-develops and commercializes through a collaboration with Incyte Corporation.
What sector is SYNDAX PHARMACEUTICALS INC (SNDX) in?
SYNDAX PHARMACEUTICALS INC (SNDX) is classified in the Health Care sector. Its industry is Clinical-stage biopharmaceutical oncology and fibrotic disease therapies. It trades on NASDAQ.
Who are SYNDAX PHARMACEUTICALS INC's (SNDX) competitors?
Notable peers of SYNDAX PHARMACEUTICALS INC (SNDX) include Incyte, Novartis, Bristol Myers Squibb, Gilead Sciences and AbbVie. This peer set is informational only — not financial advice.
Is SYNDAX PHARMACEUTICALS INC (SNDX) overbought or oversold right now?
SYNDAX PHARMACEUTICALS INC (SNDX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SNDX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.